Tag Archives: Thomson Reuters

BRIC Nations' "Blossoming Healthcare Budgets" Revive Clinical Trials Opportunities

While some clinical trial sponsors have been driven out of the BRIC nations, a rise in rank for each country — Brazil, Russia, India, China — is expected over the next four years, indicating “blossoming healthcare budgets and markets that are ripe with opportunities for development”. According to a Thomson Reuters report, Overcoming Clinical Challenges in BRIC […]
Posted in Emerging Markets, Europe, Global, R&D | Also tagged , , | Leave a comment

Study Points to Dramatic Drop In R&D Expenditure

Pharma expenditure on R&D has dropped to an estimated $68 billion, according to Thomson Reuters’ 2011 Pharmaceutical R&D Factbook. The three-year low demonstrates the receding trends of drug success, the amount of drugs entering Phase I and II trials and the number of new molecular entities (NMEs) launched in the global market.
Posted in Global, Guest Blog, R&D | Also tagged , , , | 1 Comment

Two 'Most Promising' New Drugs Face Setbacks in US

Two of the drugs named “most promising” in Thomson Reuters’ recent quarterly report hit snags in the US, despite European approval. Those two products – AstraZeneca’s Brilique (Brilinta in the US), a blood thinner, and Pharming’s Ruconest (Rhucin in the US) – were held up during FDA’s review process. Brilique (ticagrelor), AstraZeneca’s leading pipeline drug, […]
Posted in FDA, Global, R&D, Regulatory, Sales | Also tagged , , , , | Leave a comment
  • Categories

  • Meta